Inclusion Criteria : 
  -  Established diagnosis of UC for at least 3 months prior to screening , with minimum disease extent of 15 cm from the anal verge
  -  Mildly to moderately active UC
  -  Inadequate response to ongoing treatment with oral mesalamine ≥ 2.4 g / day for ≥ 4 weeks from screening visit
Exclusion Criteria : 
  -  Possible or confirmed diagnosis of Crohn's Disease or other forms of inflammatory bowel disorders
  -  Ongoing or failed prior treatment for UC with methotrexate , azathioprine , 
     6 - mercaptopurine , cyclosporine , tofacitinib , mycophenolate mofetil , sirolimus ( rapamycin )  , thalidomide , tacrolimus ( FK - 506 )  , or biologics ( e. g. , TNF - alpha - antagonists , anti - integrin therapies , or agents targeting IL - 12 or IL - 23 , etc. ) 
  -  Any immunosuppressive condition or treatment with immunosuppressive medications
  -  History of prior surgical intervention in any region of the gastrointestinal tract ( excluding minor surgery ) 
  -  Prior diagnosis of any cardiovascular , renal , hepatic , endocrine , infectious , hematological , oncologic , neuro - psychiatric or immune - mediated disorder , which in the opinion of the Principal Investigator might impact the subject's safety or compliance , or the interpretation of results
  -  Treatment with any other investigational drugs ≤ 12 weeks prior to baseline visit
  -  The participant has a condition or is in a situation which , in the Principal Investigator's opinion , may put the participant at significant risk , may confound the study results , or may interfere significantly with the participant's participation in the study